The prototype of glycogen phosphorylase

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, with rising mortality rates linked to hyperglycemia.
• Dysregulated glycogen metabolism, particularly elevated blood glucose levels, is a primary contributor to T2DM pathogenesis.
• Targeting key enzymes in glycogen metabolism pathways offers a promising therapeutic strategy for T2DM management.

Purpose of the Study:

• To identify and characterize novel antihyperglycemic agents.
• To investigate glycogen phosphorylase as a molecular target for antidiabetic drug design.
• To explore structure-based inhibitor design for targeting the enzyme's catalytic site.

Main Methods:

• Interdisciplinary approach integrating organic synthesis, enzyme kinetics, and X-ray crystallography.
• Structure-based drug design utilizing insights into the enzyme's catalytic site.
• Physiological experiments to evaluate the efficacy of identified inhibitors.

Main Results:

• Identification of potent inhibitors across various chemical classes targeting glycogen phosphorylase.
• Detailed characterization of inhibitor interactions within the enzyme's catalytic site through crystallographic studies.
• Demonstration of the potential of these inhibitors as antihyperglycemic agents.

Conclusions:

• Glycogen phosphorylase is a validated molecular target for the development of new antidiabetic drugs.
• Structure-based inhibitor design is an effective strategy for discovering potent antihyperglycemic compounds.
• The identified inhibitors represent promising leads for future therapeutic interventions in type 2 diabetes.